2024-02-08T07:10:13Z
2024-02-08T07:10:13Z
2023
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. We acknowledge support from the Spanish Ministry of Science and Innovation to the EMBL partnership, from the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya. AB is supported by an FPI fellowship from the Spanish Ministry of Science and Innovation (PRE2019-087574). LA received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement number 101034290 and CEX2020-001049-S financed by MCIN/AEI/10.13039/501100011033. RB was supported by a Junior Leader Fellowship from the la Caixa foundation and grants from the Spanish Ministry of Science and Innovation (RTI2018-096359-A-I00) and the European Hematology Association (EHA, Advanced Research Grant), and is supported by grants from the European Research Council (101039265) and the Spanish Ministry of Science and Innovation (PID2021-123635NB-I00).
Article
Published version
English
DNA methylation; Epigenomics; Hematological malignancies; Hematopoiesis; Single-cell technologies
Frontiers
Front Mol Biosci. 2023 Oct 26;10:1286716
info:eu-repo/grantAgreement/EC/H2020/101034290
info:eu-repo/grantAgreement/ES/2PE/PRE2019-087574
info:eu-repo/grantAgreement/ES/2PE/RTI2018-096359-A-I00
info:eu-repo/grantAgreement/ES/3PE/PID2021-123635NB-I00
© 2023 Albinati, Bianchi and Beekman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (http://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
http://creativecommons.org/licenses/by/4.0/